Sorry, you need to enable JavaScript to visit this website.

RAPAMUNE® (sirolimus) Overdosage


Reports of overdose with Rapamune have been received; however, experience has been limited. In general, the adverse effects of overdose are consistent with those listed in the adverse reactions section [see Adverse Reactions (6)].

General supportive measures should be followed in all cases of overdose. Based on the low aqueous solubility and high erythrocyte and plasma protein binding of sirolimus, it is anticipated that sirolimus is not dialyzable to any significant extent. In mice and rats, the acute oral LD50 was greater than 800 mg/kg.

What's New

No Current Announcements.

Contact Pfizer Medical

Report an Adverse Event


Please enter your search term(s) for RAPAMUNE®